Trials / Completed
CompletedNCT03802786
Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Imeglimin in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Poxel SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, single-centre, open-label, parallel-group study in subjects with moderate hepatic impairment and subjects with normal hepatic function. Child-Pugh (CP) scoring will be used to determine hepatic impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imeglimin | Single administration dose of imeglimin |
Timeline
- Start date
- 2018-11-06
- Primary completion
- 2019-07-03
- Completion
- 2019-07-08
- First posted
- 2019-01-14
- Last updated
- 2020-08-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03802786. Inclusion in this directory is not an endorsement.